000 02277nam a22003615i 4500
001 292360
003 MX-SnUAN
005 20170705134225.0
007 cr nn 008mamaa
008 150903s2014 gw | o |||| 0|eng d
020 _a9783319009780
_99783319009780
024 7 _a10.1007/9783319009780
_2doi
035 _avtls000345828
039 9 _a201509030908
_bVLOAD
_c201405050326
_dVLOAD
_y201402061345
_zstaff
040 _aMX-SnUAN
_bspa
_cMX-SnUAN
_erda
050 4 _aRM281
100 1 _aGiese, Matthias.
_eeditor.
_9324069
245 1 0 _aMolecular Vaccines :
_bFrom Prophylaxis to Therapy - Volume 2 /
_cedited by Matthias Giese.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2014.
300 _axxviii, 870 páginas 98 ilustraciones, 74 ilustraciones en color.
_brecurso en línea.
336 _atexto
_btxt
_2rdacontent
337 _acomputadora
_bc
_2rdamedia
338 _arecurso en línea
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
_2rda
500 _aSpringer eBooks
505 0 _aNon-infectious and non-cancer vaccines -- Adjuvants and nanotechnology -- In silico and delivery systems -- Patenting, manufacturing, registration.
520 _aThis title discusses all aspects of non-infectious and non-cancer– so called NINC – vaccines. Hypertension, diabetes and allergy vaccine development are referred to as well as the use of adjuvants and nanotechnology in vaccine development. The way of novel vaccines from bench to preclinical to clinical studies and launch to the market under EMEA (European Medicines Agency) and FDA (Food and Drug Administration) guidelines are described in-depth. Practical perspectives of patentability of vaccines are discussed. The book is therefore of interest for researchers and clinicians engaged in vaccine development and molecular vaccine application.
590 _aPara consulta fuera de la UANL se requiere clave de acceso remoto.
710 2 _aSpringerLink (Servicio en línea)
_9299170
776 0 8 _iEdición impresa:
_z9783319009773
856 4 0 _uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-3-319-00978-0
_zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942 _c14
999 _c292360
_d292360